Lucie Peuvrel

Nantes, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications

Benign-Appearing Palmar Lesion in a Young Woman: The Importance of Considering Digital Papillary Adenocarcinoma.

Benign-Appearing Palmar Lesion in a Young Woman: The Importance of Considering Digital Papillary Adenocarcinoma.

Journal: Cureus
Published: May 06, 2026

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.

Journal: European journal of cancer (Oxford, England : 1990)
Published: September 22, 2025

Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.

Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.

Journal: JAMA dermatology
Published: December 23, 2024

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study.

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study.

Journal: Acta dermato-venereologica
Published: August 06, 2024

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Journal: Cancers
Published: April 24, 2023

Cemiplimab-induced cytokine-release syndrome: second case reported and review of the literature.

Cemiplimab-induced cytokine-release syndrome: second case reported and review of the literature.

Journal: Immunotherapy
Published: February 15, 2023

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Journal: Annales de dermatologie et de venereologie
Published: February 07, 2023

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.

Journal: Cancers
Published: June 06, 2021

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 30, 2021

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.

Chemotherapy efficacy after first-line immunotherapy in 18 advanced melanoma patients.

Journal: Medicine
Published: July 25, 2020

Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.

Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.

Journal: European journal of dermatology : EJD
Published: August 08, 2019

First case of cutaneous sarcoidosis within tattoos under durvalumab.

First case of cutaneous sarcoidosis within tattoos under durvalumab.

Journal: International journal of dermatology
Published: February 12, 2019
Showing 1-12 of 64

Last Updated: 09/26/2026